FBRX – Forte Biosciences Inc
Float Short %
0.93
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.08
EPS Last/This Y
7.74
EPS This/Next Y
1.11
Price
10.56
Target Price
52.25
Analyst Recom
1
Performance Q
-15.79
Relative Volume
0.41
Beta
2.97
Ticker: FBRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | FBRX | 11.78 | 4.00 | 999.99 | 20 |
| 2025-08-18 | FBRX | 11.92 | 1.50 | 999.99 | 5 |
| 2025-08-19 | FBRX | 11.73 | 41.50 | 999.99 | 85 |
| 2025-08-20 | FBRX | 11.67 | 81.50 | 999.99 | 165 |
| 2025-08-21 | FBRX | 11.11 | 91.50 | 999.99 | 185 |
| 2025-08-22 | FBRX | 11.76 | 91.50 | 999.99 | 185 |
| 2025-08-25 | FBRX | 11.22 | 101.50 | 999.99 | 205 |
| 2025-08-26 | FBRX | 11.02 | 101.50 | 999.99 | 205 |
| 2025-08-27 | FBRX | 11.24 | 106.50 | 999.99 | 215 |
| 2025-08-28 | FBRX | 11.21 | 106.50 | 999.99 | 215 |
| 2025-08-29 | FBRX | 11 | 106.50 | 999.99 | 215 |
| 2025-09-02 | FBRX | 10.9 | 106.50 | 999.99 | 215 |
| 2025-09-03 | FBRX | 10.96 | 111.50 | 999.99 | 225 |
| 2025-09-04 | FBRX | 10.781 | 112.00 | 999.99 | 226 |
| 2025-09-05 | FBRX | 11.36 | 112.00 | 999.99 | 226 |
| 2025-09-08 | FBRX | 10.99 | 112.00 | 999.99 | 226 |
| 2025-09-09 | FBRX | 11.07 | 112.00 | 999.99 | 226 |
| 2025-09-10 | FBRX | 10.94 | 112.00 | 999.99 | 226 |
| 2025-09-11 | FBRX | 10.48 | 112.00 | 999.99 | 226 |
| 2025-09-12 | FBRX | 10.52 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | FBRX | 11.68 | 83.6 | - | -4.38 |
| 2025-08-18 | FBRX | 12.05 | 83.6 | - | -4.38 |
| 2025-08-19 | FBRX | 11.75 | 83.6 | - | -4.38 |
| 2025-08-20 | FBRX | 11.68 | 83.6 | - | -4.38 |
| 2025-08-21 | FBRX | 11.29 | 83.6 | - | -4.38 |
| 2025-08-22 | FBRX | 11.54 | 76.5 | - | -4.43 |
| 2025-08-25 | FBRX | 11.31 | 76.5 | - | -4.43 |
| 2025-08-26 | FBRX | 11.26 | 76.5 | - | -4.43 |
| 2025-08-28 | FBRX | 11.23 | 76.5 | - | -4.43 |
| 2025-08-29 | FBRX | 10.97 | 76.5 | - | -4.43 |
| 2025-09-02 | FBRX | 10.99 | 76.5 | - | -4.43 |
| 2025-09-03 | FBRX | 11.00 | 76.5 | - | -4.43 |
| 2025-09-04 | FBRX | 10.80 | 76.5 | - | -4.43 |
| 2025-09-05 | FBRX | 11.26 | 76.5 | - | -4.43 |
| 2025-09-08 | FBRX | 11.13 | 76.5 | - | -4.43 |
| 2025-09-09 | FBRX | 10.91 | 76.5 | - | -4.43 |
| 2025-09-10 | FBRX | 10.93 | 76.5 | - | -4.43 |
| 2025-09-11 | FBRX | 10.46 | 76.5 | - | -4.43 |
| 2025-09-12 | FBRX | 10.56 | 76.5 | - | -4.43 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | FBRX | 0.00 | 32.79 | 1.17 |
| 2025-08-18 | FBRX | 0.00 | 26.65 | 1.15 |
| 2025-08-19 | FBRX | 0.00 | 26.65 | 1.22 |
| 2025-08-20 | FBRX | 0.00 | 26.65 | 1.22 |
| 2025-08-21 | FBRX | 0.00 | 26.65 | 1.22 |
| 2025-08-22 | FBRX | 0.00 | 26.65 | 1.22 |
| 2025-08-25 | FBRX | 0.00 | 359.38 | 1.22 |
| 2025-08-26 | FBRX | 0.00 | 359.38 | 1.22 |
| 2025-08-27 | FBRX | 0.00 | 359.38 | 0.96 |
| 2025-08-28 | FBRX | 0.00 | 359.38 | 0.96 |
| 2025-08-29 | FBRX | 0.00 | 359.38 | 0.96 |
| 2025-09-02 | FBRX | 0.00 | 359.71 | 0.96 |
| 2025-09-03 | FBRX | 0.00 | 359.71 | 0.96 |
| 2025-09-04 | FBRX | 0.00 | 359.71 | 0.96 |
| 2025-09-05 | FBRX | 0.00 | 359.71 | 0.96 |
| 2025-09-08 | FBRX | 0.00 | 360.08 | 0.96 |
| 2025-09-09 | FBRX | 0.00 | 360.08 | 0.96 |
| 2025-09-10 | FBRX | 0.00 | 360.08 | 0.96 |
| 2025-09-11 | FBRX | 0.00 | 360.08 | 0.93 |
| 2025-09-12 | FBRX | 0.00 | 360.08 | 0.93 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.96
Avg. EPS Est. Current Quarter
-1.07
Avg. EPS Est. Next Quarter
-1.04
Insider Transactions
Institutional Transactions
360.08
Beta
2.97
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
19
Sentiment Score
62
Actual DrawDown %
99.2
Max Drawdown 5-Year %
-99.7
Target Price
52.25
P/E
Forward P/E
PEG
P/S
P/B
1.32
P/Free Cash Flow
EPS
-7.99
Average EPS Est. Cur. Y
-4.43
EPS Next Y. (Est.)
-3.33
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.41
Return on Equity vs Sector %
-67.9
Return on Equity vs Industry %
-54.8
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.05
EBIT Estimation
Forte Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 17
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
stock quote shares FBRX – Forte Biosciences Inc Stock Price stock today
news today FBRX – Forte Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FBRX – Forte Biosciences Inc yahoo finance google finance
stock history FBRX – Forte Biosciences Inc invest stock market
stock prices FBRX premarket after hours
ticker FBRX fair value insiders trading